SCIO-469: SCIO enrolled 42 of 120 patients in a dose-ranging, placebo-controlled Phase IIa trial in RA patients who are receiving methotrexate.

Scios Inc. (SCIO), Sunnyvale, Calif. Product: SCIO-469 Business: Autoimmune/Inflammation Therapeutic category: Signal transduction, Cytokine production Target: p38 MAP kinase Description: Oral small m...